Zalevsky Jonathan sold $13K of NKTR

Nektar Therapeutics claims Eli Lilly & Co. may owe it nearly $1 billion in damages for allegedly breaching their Rezpeg deal, according to testimony in a California federal court. The amount is based on Nektar's expert's calculation of lost profits and other factors.

Rezpegaldesleukin, a drug developed by Nektar Therapeutics, significantly reduced disease severity in moderate-to-severe atopic dermatitis patients in a phase 2b trial. All doses showed improved EASI scores and secondary endpoints compared to placebo. The treatment increased regulatory T cells and reduced key AD biomarkers, with common side effects including injection-site reactions. The study was funded by Nektar Therapeutics, and some authors have financial ties to the company.

Nektar Therapeutics (NKTR) stock is in focus after positive Phase 2b data for rezpegaldesleukin in The Lancet. The stock is up 67% YTD but trades 50% below the average analyst target of $144.40. NKTR has a robust cash position and faces risks like ongoing losses and reliance on trial outcomes.

Nektar Therapeutics (NKTR) reported Q2 2026 results showing increased cash and investments ($1.02B) due to equity raises, but still no commercial revenue. Net loss was $40.6M, down slightly from Q2 2025. The company's focus is on advancing its pipeline, particularly REZPEG, with management emphasizing clinical progress over near-term solvency.

Nektar Therapeutics (NKTR) reported Q2 earnings, highlighting a $1.02B cash balance and Phase 3 trials for rezpegaldesleukin in atopic dermatitis and alopecia areata. The company expects top-line data in mid-2028 and a potential Biologics License Application submission in 2029. NKTR's operating loss widened to $42.3M, with R&D spending expected to increase. The company raised $373.8M in April 2026 to fund operations.

Nektar Therapeutics reported Q2 2026 earnings with noncash royalty revenue of $10.1M, a net loss of $40.6M, and cash/investments of $1.02B. The company initiated Phase 3 trials for rezpegaldesleukin and updated full-year guidance, including revenue of $40M-$45M and end-of-year cash of $815M-$840M. Management expects a cash runway into Q3 2028, supported by a recent public offering.